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background: The CYP2C19 loss-of-function polymorphisms (*2 and *3) lead to reduced generation of the active metabolite of clopidogrel 
to inadequate response to clopidogrel, and are, similarly to high on-treatment platelet reactivity (HPR), which both associated with recurrent 
atherothrombotic events following coronary stent implantation. We hypothesized that an aggregate risk evaluated by CYP2C19 loss-of-function allele 
genotyping combined with thrombelastograph (TEG) platelet-mapping assay would be a powerful predictor of recurrent cardiovascular ischemic 
events. This study sought to determine CYP2C19 loss-of-function allele genotyping combined with TEG assay for enhanced prediction of adverse 
cardiovascular ischemic events.
methods: CYP2C19 loss-of-function allele (*2 and *3) genotyping and platelet function testing by TEG were performed in 1104 Chinese patients 
treated with clopidogrel undergoing elective coronary stenting. Adverse cardiovascular ischemic outcomes comprised of cardiovascular death, 
nonfatal myocardial infarction, target vessel revascularization, and stent thrombosis. The follow-up period was 12 months. Survival analyses were 
performed with models adjusted for established risk factors.
results: Hazard ratios (HRs) for cardiovascular ischemic outcomes based on the two testing were as follows: CYP2C19 genotyping: carriers of 
CYP2C19 loss-of-function alleles, HR: 2.515, P = 0.021; adenosine diphosphate (ADP) induced platelet inhibition ≤ 30% by TEG, HR: 1.992, P 
=0.038. An ischemic risk score between 0 and 2 was calculated based on the number of positive results of these tests. Compared with the group 
with a 0 score, HRs for adverse cardiovascular outcomes were 4.078 for those with score of 2 (p = 0.005). However, there was no significant 
difference between the group with the score of 0 and the group with the score of 1 (HR: 1.701, p = 0.264).
Conclusion: An ischemic risk score based on CYP2C19 loss-of-function allele genotyping and platelet function by TEG assay is a predictor of future 
risk of adverse cardiovascular outcomes in Chinese patients treated with clopidogrel undergoing coronary stent implantation.
